284 related articles for article (PubMed ID: 25030803)
1. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
Marx CE; Lee J; Subramaniam M; Rapisarda A; Bautista DC; Chan E; Kilts JD; Buchanan RW; Wai EP; Verma S; Sim K; Hariram J; Jacob R; Keefe RS; Chong SA
Psychopharmacology (Berl); 2014 Sep; 231(17):3647-62. PubMed ID: 25030803
[TBL] [Abstract][Full Text] [Related]
2. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
Marx CE; Keefe RS; Buchanan RW; Hamer RM; Kilts JD; Bradford DW; Strauss JL; Naylor JC; Payne VM; Lieberman JA; Savitz AJ; Leimone LA; Dunn L; Porcu P; Morrow AL; Shampine LJ
Neuropsychopharmacology; 2009 Jul; 34(8):1885-903. PubMed ID: 19339966
[TBL] [Abstract][Full Text] [Related]
3. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.
Marx CE; Bradford DW; Hamer RM; Naylor JC; Allen TB; Lieberman JA; Strauss JL; Kilts JD
Neuroscience; 2011 Sep; 191():78-90. PubMed ID: 21756978
[TBL] [Abstract][Full Text] [Related]
4. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.
Ritsner MS; Bawakny H; Kreinin A
Psychiatry Clin Neurosci; 2014 Jun; 68(6):432-40. PubMed ID: 24548129
[TBL] [Abstract][Full Text] [Related]
5. Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Kardashev A; Ratner Y; Ritsner MS
Clin Schizophr Relat Psychoses; 2018; 12(1):31-41. PubMed ID: 26218236
[TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Kreinin A; Bawakny N; Ritsner MS
Clin Schizophr Relat Psychoses; 2017; 10(4):201-210. PubMed ID: 24496044
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
[TBL] [Abstract][Full Text] [Related]
12. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
13. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
14. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension.
Harvey PD; Siu CO; Hsu J; Cucchiaro J; Maruff P; Loebel A
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1373-82. PubMed ID: 24035633
[TBL] [Abstract][Full Text] [Related]
15. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC; Buchanan RW; Keefe RS; Kern R; McMahon RP; Green MF; Lieberman J; Goff DC; Csernansky JG; McEvoy JP; Jarskog F; Seidman LJ; Gold JM; Kimhy D; Nolan KS; Barch DS; Ball MP; Robinson J; Marder SR
Schizophr Res; 2012 Apr; 136(1-3):25-31. PubMed ID: 22169248
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia.
Buchanan RW; Weiner E; Kelly DL; Gold JM; Chen S; Zaranski J; Blatt F; Wehring H; Carpenter WT
J Clin Psychopharmacol; 2020; 40(5):444-450. PubMed ID: 32796391
[TBL] [Abstract][Full Text] [Related]
17. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
18. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial.
Mahncke HW; Kim SJ; Rose A; Stasio C; Buckley P; Caroff S; Duncan E; Yasmin S; Jarskog LF; Lamberti JS; Nuechterlein K; Strassnig M; Velligan D; Ventura J; Walker T; Stroup TS; Keefe RSE
Schizophr Res; 2019 Jun; 208():182-189. PubMed ID: 30930034
[TBL] [Abstract][Full Text] [Related]
20. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
